Holger Reithinger PhD
Senior Advisor
Developing Anticalin® product candidates to help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).
Industry
Biotech
Status
Past
Location
Germany
Forbion team